tradingview.com
Cure8 news brief
Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3? - TradingView
Medications
Risankizumab
Upadacitinib
Adalimumab
IL-23 inhibitor
JAK inhibitor
Anti-TNF
Market or Business News
Why This Matters
Patients and clinicians may see continued availability and promotion of Skyrizi and Rinvoq across IBD indications, which can affect prescribing options and market competition. Sales growth and approvals also influence payer coverage and pricing decisions that affect patient access.
Who Should Pay Attention
Adult patients with IBD (UC or Crohn’s), patients on biologics or JAK inhibitors, clinicians who prescribe immunology drugs, and researchers or stakeholders tracking pharma market dynamics.
Study Snapshot
Story typeBusiness news
Evidence typeMarket or Business News
Source depthFull source text
What To Know
AbbVie's newer immunology drugs—Skyrizi and Rinvoq—are highlighted as central to the company’s revenue growth, and the article links their uptake to performance in IBD (UC and CD). It also flags competitive pressures from other makers (J&J, Eli Lilly) and the impact of biosimilars and new approvals on market share.
The report is a market/earnings preview from Zacks Investment Research republished on TradingView, so it frames the drugs’ roles in corporate sales and investor expectations rather than reporting clinical results or new safety/efficacy data.
If you follow IBD treatment availability or industry trends, this gives a high-level sense of which branded drugs are driving commercial growth and which competitors could affect future access or prescribing patterns.
Keep In Mind
This is a business/market analysis summarizing sales estimates and competitive dynamics; it does not present new clinical data. The source is a Zacks Investment Research piece republished on TradingView—interpret findings as commercial/financial commentary rather than clinical guidance.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationtradingview.com
Indexed viaGoogle News
Source typeWeb article
PublishedOct 12, 2026, 4:32 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next - TradingView
This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance? - TradingView
Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...